Shanghai Haohai Biological Technology Co., Ltd. (6826.HK)
HKD 26.85
(-1.65%)
HKD 26.85
(-1.65%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.63 Billion CNY | 25.27% |
| 2022 | 2.1 Billion CNY | 20.19% |
| 2021 | 1.75 Billion CNY | 32.14% |
| 2020 | 1.32 Billion CNY | -16.99% |
| 2019 | 1.59 Billion CNY | 3.21% |
| 2018 | 1.54 Billion CNY | 14.94% |
| 2017 | 1.34 Billion CNY | 58.0% |
| 2016 | 851.15 Million CNY | 28.2% |
| 2015 | 663.91 Million CNY | 28.68% |
| 2014 | 515.94 Million CNY | 28.64% |
| 2013 | 401.08 Million CNY | 32.34% |
| 2012 | 303.06 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 645.99 Million CNY | -1.09% |
| 2024 Q2 | 758.44 Million CNY | 17.41% |
| 2023 Q2 | 694.45 Million CNY | 13.61% |
| 2023 Q3 | 676.08 Million CNY | -2.65% |
| 2023 Q4 | 653.12 Million CNY | -3.4% |
| 2023 Q1 | 611.25 Million CNY | 17.35% |
| 2023 FY | 2.63 Billion CNY | 25.27% |
| 2022 FY | 2.1 Billion CNY | 20.19% |
| 2022 Q4 | 520.87 Million CNY | -16.83% |
| 2022 Q3 | 626.29 Million CNY | 30.99% |
| 2022 Q2 | 478.13 Million CNY | 0.0% |
| 2022 Q1 | 478.13 Million CNY | 0.59% |
| 2021 Q1 | 422.93 Million CNY | -2.16% |
| 2021 Q3 | 423.57 Million CNY | 0.15% |
| 2021 Q4 | 475.31 Million CNY | 12.21% |
| 2021 FY | 1.75 Billion CNY | 32.14% |
| 2021 Q2 | 422.93 Million CNY | 0.0% |
| 2020 Q4 | 432.27 Million CNY | 9.11% |
| 2020 FY | 1.32 Billion CNY | -16.99% |
| 2020 Q1 | 153.61 Million CNY | -65.92% |
| 2020 Q2 | 342.34 Million CNY | 122.86% |
| 2020 Q3 | 396.19 Million CNY | 15.73% |
| 2019 Q3 | 359.38 Million CNY | -24.02% |
| 2019 Q2 | 473.02 Million CNY | 51.47% |
| 2019 FY | 1.59 Billion CNY | 3.21% |
| 2019 Q1 | 312.29 Million CNY | -20.41% |
| 2019 Q4 | 450.79 Million CNY | 25.43% |
| 2018 Q1 | 380.53 Million CNY | 2.88% |
| 2018 FY | 1.54 Billion CNY | 14.94% |
| 2018 Q4 | 392.37 Million CNY | 0.0% |
| 2018 Q3 | 392.37 Million CNY | 3.11% |
| 2018 Q2 | 380.53 Million CNY | 0.0% |
| 2017 FY | 1.34 Billion CNY | 58.0% |
| 2017 Q1 | 302.56 Million CNY | 26.54% |
| 2017 Q2 | 302.56 Million CNY | 0.0% |
| 2017 Q3 | 369.86 Million CNY | 22.24% |
| 2017 Q4 | 369.86 Million CNY | 0.0% |
| 2016 Q2 | 186.46 Million CNY | 0.0% |
| 2016 FY | 851.15 Million CNY | 28.2% |
| 2016 Q3 | 239.11 Million CNY | 28.23% |
| 2016 Q1 | 186.46 Million CNY | 6.31% |
| 2016 Q4 | 239.11 Million CNY | 0.0% |
| 2015 Q2 | 156.55 Million CNY | 0.0% |
| 2015 Q4 | 175.4 Million CNY | 0.0% |
| 2015 FY | 663.91 Million CNY | 28.68% |
| 2015 Q1 | 156.55 Million CNY | 10.38% |
| 2015 Q3 | 175.4 Million CNY | 12.04% |
| 2014 Q1 | 116.14 Million CNY | 7.2% |
| 2014 Q4 | 141.82 Million CNY | 0.0% |
| 2014 FY | 515.94 Million CNY | 28.64% |
| 2014 Q3 | 141.82 Million CNY | 22.12% |
| 2014 Q2 | 116.14 Million CNY | 0.0% |
| 2013 Q4 | 108.33 Million CNY | 0.0% |
| 2013 Q1 | 92.2 Million CNY | 0.0% |
| 2013 FY | 401.08 Million CNY | 32.34% |
| 2013 Q3 | 108.33 Million CNY | 17.5% |
| 2013 Q2 | 92.2 Million CNY | 0.0% |
| 2012 FY | 303.06 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 484.71 Million HKD | -443.596% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.32 Billion HKD | 50.497% |